Fibroblast growth factor-21 (FGF-21) is a new member of the FGF super-family and an important endogenous regulator of glucose and lipid metabolism. It has been proposed as a therapeutic target for diabetes and obesity. Its function in the central nervous system (CNS) remains unknown. Previous studies from our laboratory demonstrated that aging primary neurons are more vulnerable to glutamate-induced excitotoxicity, and that co-treatment with the mood stabilizers lithium and valproic acid (VPA) induces synergistic neuroprotective effects. This study sought to identify molecule(s) involved in these synergistic effects. We found that FGF-21 mRNA was selectively and markedly elevated by co-treatment with lithium and VPA in primary rat brain neurons. FGF-21 protein levels were also robustly increased in neuronal lysates and culture medium following lithium-VPA co-treatment. Combining glycogen synthase kinase-3 (GSK-3) inhibitors with VPA or histone deacetylase (HDAC) inhibitors with lithium synergistically increased FGF-21 mRNA levels, supporting that synergistic effects of lithium and VPA are mediated via GSK-3 and HDAC inhibition, respectively. Exogenous FGF-21 protein completely protected aging neurons from glutamate challenge. This neuroprotection was associated with enhanced Akt-1 activation and GSK-3 inhibition. Lithium-VPA co-treatment markedly prolonged lithium-induced Akt-1 activation and augmented GSK-3 inhibition. Akt-1 knockdown markedly decreased FGF-21 mRNA levels and reduced the neuroprotection induced by FGF-21 or lithium-VPA co-treatment. In addition, FGF-21 knockdown reduced lithium-VPA co-treatment-induced Akt-1 activation and neuroprotection against excitotoxicity. Together, our novel results suggest that FGF-21 is a key mediator of the effects of these mood stabilizers and a potential new therapeutic target for CNS disorders.
INTRODUCTION
Fibroblast growth factor-21 (FGF-21) is a recently discovered metabolic regulator shown to facilitate glucose and lipid metabolism. 1 When administered systemically to obese, insulinresistant rodents and diabetic monkeys, FGF-21 enhances energy utilization, improves insulin sensitivity and induces weight loss. [2] [3] [4] [5] [6] By interacting with its specific cell surface receptors and its co-receptor β-Klotho, FGF-21 also regulates the expression of genes involved in gluconeogenesis, lipogenesis, lipolysis and fatty acid oxidation. 3, 7, 8 During fasting, FGF-21 is induced in the liver, the major site of its production, by mechanisms involving the activation of the nuclear receptor peroxisome proliferatoractivated receptor-α (PPARα). 1, 9 In addition, FGF-21 is upregulated in adipose tissue through PPARγ, 10 and controls PPARγ activity in an autocrine manner to enhance adipogenesis and to mediate the clinical and side effects of PPARγ agonists thiazolidinediones. 11 In clinical studies, higher serum levels of FGF-21 were found in patients with metabolic disorders such as type 2 diabetes, fatty liver disease and coronary artery disease. [12] [13] [14] This suggests that these metabolic disorders involve FGF-21 resistance or compensatory response to specific metabolic stress. Interestingly, intracerebral ventricular injection of human recombinant FGF-21 in rats increases hepatic insulin sensitivity and metabolic rate in dietinduced obesity. 15 These results suggest that the central nervous system (CNS) is likely a significant target for the potential benefits of FGF-21 in the treatment of diabetes and obesity.
Emerging evidence suggests that FGF-21 has some protective effects. For example, FGF-21 has been shown to improve the survival and function of pancreatic β-cells by activating protein kinase B (Akt) and extracellular signal-related kinase (ERK) 44/42 signaling pathways, 16 protect animals from the adverse effects of lipopolysaccharide and sepsis 17 as well as against cardiac hypertrophy, 18 and prevent palmitate-induced insulin resistance by inhibiting the activation of stress kinase and NF-κB. 19 Autophagy deficiency and the resultant mitochondrial dysfunction have also been reported to enhance FGF-21 expression and collectively protect against diet-induced obesity and insulin resistance. 20 However, whether FGF-21 is expressed in brain neurons, or exhibits specific functions such as neuroprotection, remains unknown.
Recent studies have observed that mood-stabilizing drugs used to treat bipolar disorder, notably lithium and valproic acid (VPA), have neuroprotective properties against multiple insults in both in vivo and in vitro experimental settings as well as in clinical studies. By inhibiting glycogen synthase kinase-3 (GSK-3), lithium modulates transcriptional regulation of genes involved in neuroprotection and neurotrophism such as B-cell lymphoma 2 (Bcl-2), p53, Bcl-2 associated X protein (Bax) and brain-derived neurotrophic factor (BDNF). 21, 22 In contrast, VPA has been identified as a pan inhibitor of histone deacetylases (HDACs). 23, 24 Via HDAC inhibition, VPA remodels chromatin structure to activate transcriptional factors, thereby inducing prominent molecules, including heat-shock protein-70 (HSP70), Bcl-2, α-synuclein, BDNF and vascular endothelial growth factor (VEGF). 21, 25, 26 In primary young cultures of brain neurons including cerebellar granular cells (CGCs), pretreatment with either lithium or VPA robustly protects against glutamate-induced, N-methyl D-aspartate (NMDA) receptormediated excitotoxicity. 27, 28 Interestingly, in aging CGCs, treatment with either lithium or VPA alone produces only marginal neuroprotection against excitotoxicity; in contrast, combined treatment with these two drugs induces synergistic neuroprotective effects. 28 The synergic neuroprotective effects of lithium-VPA co-treatment are associated with enhancement of GSK-3 inhibition induced by lithium alone. 28 However, the gene whose expression is critical for the neuroprotective synergy remains unidentified. In this study, we used mRNA microarray and quantitative PCR to demonstrate for the first time that FGF-21 is robustly induced by co-treatment with the mood stabilizers lithium and VPA. Further, we show that FGF-21 has a remarkable neuroprotective role via mechanisms involving Akt-1 activation and is part of the molecular complex underlying the synergistic neuroprotection induced by mood stabilizers. In addition, our results suggest that FGF-21 is a potential new target for the treatment of brain disorders.
MATERIALS AND METHODS

Primary rat CGC, hippocampal and cerebral cortical neuronal cultures
Eight-day-old Sprague-Dawley rats were used to prepare CGCs as previously described 28 and according to procedures approved by the NIH Animal Care and Use Committee. Dissociated cells were resuspended in 2% serum-free Gem21 (Gemini, West Sacramento, CA, USA) /neurobasal medium (Life Technologies, Grand Island, NY, USA) and plated at a density of 1.6 × 10 6 cells per ml on poly-L-lysine pre-coated 96-well plates (Corning Incoporated, Corning, NY, USA), six-well plates (BD Bioscience, Franklin Lakes, NJ, USA) or chamber slides (Nalge Nunc International, Rochester, NY, USA). Cytosine arabinofuranoside (10 μM; Arac) was added to the cultures about 24 h after plating to arrest the growth of non-neuronal, replicating cells. The cells were maintained at 37°C in the presence of 5% CO 2 /95% air in a humidified incubator. During experiments, more than 92% of cells represented neurons.
The brains of 18-day-old rat embryos were used to prepare hippocampal and cerebral cortical neuronal cells, as previously described. 27, 29 In brief, hippocampi and cortices were dissected from the embryonic brain, and cells were dissociated by trypsinization and trituration, followed by DNase treatment. The dissociated cells were resuspended in 2% serum-free Gem21/neurobasal medium and plated at a density of 7 × 10 5 cells per ml on six-well plates or chamber slides precoated with 0.01% poly-D-lysine. Five micromolar Arac was added to the cultures around 48 h after plating to arrest the replication of non-neuronal cells. Hippocampal and cortical neurons were treated with lithium, VPA, or their combination for 2 days, starting at DIV-6, as specified. At DIV-6, CGCs, hippocampal and cortical neurons were stained for neuronal marker MAP2 to show their typical mature morphologies (Supplementary Figure S1 ).
Animal treatments
Animal care was conducted according to the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. Two-month-old male CD-1 mice (20-25 g; Charles River, Wilmington, MA, USA) were grouped and housed five animals per cage with free access to food and water, and on a 12 h light/dark cycle. Mice were fed with a chow (Bio-Serv, Frenchtown, NJ, USA) containing bacon flavor alone, lithium carbonate (3 g kg − 1 ), sodium VPA (25 g kg − 1 ) or lithium carbonate-sodium VPA combination. Following dietary treatment for 28 days, mice were killed, and the brains were removed and frozen for RNA extraction. Serum concentrations of both drugs were within their therapeutic levels after chronic dietary treatment. 28 Microarray mRNA analysis CGCs were treated with 3 mM lithium chloride, 0.8 mM VPA or their combination at DIV-6, and then collected 48 h later for total RNA extraction using an RNeasy Mini Kit (Qiagen, Valencia, CA, USA). The isolated RNA (10 μg) was transcribed into double-stranded cDNA using a Superscript Double-Stranded cDNA Synthesis Kit (Life Technologies), followed by sample labeling, hybridization, scan and microarray mRNA analyses (Roche Applied Science, Indianapolis, IN, USA). Microarray data were analyzed using DNASTAR ArrayStar 5 software (DNASTAR, Madison, WI, USA).
Total RNA extraction and real-time quantitative polymerase chain reaction Total RNA from cells was collected using the RNeasy Mini-kit (Qiagen) as per the manufacturer's instructions. Each purified 2 μg RNA sample was reverse transcribed into cDNA following instructions provided by a HighCapacity cDNA Archive kit (Life Technologies). Reverse transcription (RT) reactions were performed for 10 min at 25°C, 120 min at 37°C and 5 min at 85°C. Q-PCR was conducted with TaqMan universal PCR master mix (Life Technologies) as well as with FGF-21, FGF-15, FGF-23, BDNF, GDNF, VEGF-α, PDGF-α, TGF-α, HSP70-1a, HSP70-1b and α-synuclein gene expression assays. Negative controls without reverse transcriptase were included in each assay. PCR reactions with wells were run for 2 min at 50°C, 10 min at 95°C, and 40 cycles of 15 s at 95°C and 1 min at 60°C. The 2 -ΔΔCt method was used to calculate mRNA expression levels, where C t = cycle threshold number, ΔC t = β-actin C t -target gene C t , and ΔΔC t = ΔC t control-ΔC t treated cells, and mRNA level of each sample was quantified relative to matched vehicle-treated controls with β-actin as the internal reference.
ELISA FGF-21 protein levels from the culture medium and lysates of CGCs were determined using a mouse/rat FGF-21 ELISA Kit (Aviscera Bioscience, Santa Clara, CA, USA) according to the manufacturer's protocol. In brief, 96-well microplates precoated with goat anti-rabbit immunoglobulin G (IgG) were incubated overnight by adding a FGF-21 antibody with samples or FGF-21 standards. After washing to remove unbound antibody and other substances, streptavidin conjugated to horseradish peroxidase was then added to the wells and incubated for 2 h. After washing again to remove unbound enzyme, a substrate solution was added to the wells for an additional 45-min incubation followed by washing. The enzyme reaction yielded a blue product that turned yellowish when the Stop Solution was added. The optical density of each well was detected using a microplate reader set at 450 nm, and the readings were subtracted from those at 540 nm. The intensity of the color measurement was in proportion to the amount of mouse FGF-21 bound in the initial step. Sample values were then read and calculated from the standard curve.
Measurement of cell viability
Cell viability was quantified by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) colorimetric assay for detecting mitochondrial dehydrogenase activity, as previously described. 28 In brief, CGCs in cultures were incubated with MTT (125 μg ml
) for 2 h at 37°C. After medium aspiration, the purple formazan product was dissolved in dimethyl sulfoxide (DMSO) and quantified spectrophotometrically at 540 nm. Cell viability results were expressed as percentage of the vehicle-treated control.
Analysis of chromatin condensation
CGCs grown on six-well plates were washed with ice-cold PBS, fixed with ice-cold methanol for 1 min, and chromatins were stained with Hoechst dye 33258 (5 μg ml − 1 ; Sigma-Aldrich, St. Louis, MO, USA) for 3 min at 4°C as previously described. 28 Nuclei were visualized under a Zeiss Axiovert fluorescence microscope (Carl Zeiss, Thornwood, NY, USA) at ×40 magnification.
Western blotting
CGCs were collected in lysis buffer, followed by sonication for 30 s as previously described. 29 An aliquot of 10 μg of protein was dissolved in Nupage LDS sample buffer (Life Technologies), loaded into a 4-12% , Akt-1, ERK 44/42 (1:1000; Cell Signaling Technology, Danvers, MA, USA) or β-actin (1:10 000; Sigma-Aldrich) in 0.1% Tween-20/PBS, and then with a secondary antibody (1:10:000; LI-COR Biosciences) labeled with a fluorescent dye. Reactive bands were scanned and analyzed by using the Odyssey Infrared Imaging System (LI-COR Biosciences).
Specific mRNA knockdown using lentiviral shRNA-GSK-3β (sh-GSK-3β), shRNA-FGF-21(sh-FGF-21) and shRNA-Akt-1(sh-Akt-1)
Constructs of Mission pLKO.1-puro control (sh-cont), sh-GSK-3β, sh-FGF-21 and sh-Akt-1 (Sigma-Aldrich) were used for gene knockdown studies. The respective shRNA sequences are shown in Supplementary Table S2 . Human Embryonic Kidney (HEK) 293 T/17 cells were seeded at 3 × 10 5 cells per well in six-well plates with Dulbecco's Modified Eagle's medium (DMEM) and 10% fetal bovine serum (FBS). After 24 h, cells were transfected with lentiviral shRNA constructs following the manufacturer's recommended formula (0.5 μg construct DNA, 5 μl packaging mix (Sigma-Aldrich) and 3 μl FuGENE transfection reagent (Roche Applied Science)) in 2 ml DMEM per well. Lentiviral particles secreted into the culture medium were collected 48 h after transfection and added onto six-or 96-well plates immediately after CGC plating. The next day, DMEM was replaced with 2% Gem21/neurobasal medium for gene knockdown and subsequent experiments.
Statistical analysis
Data are expressed as mean ± s.e.m. from 3-4 independent experiments. Statistical significance was analyzed using one-way analysis of variance (ANOVA) and Bonferroni's post hoc comparison, except as specified. A P-value of ⩽0.05 was considered significant.
RESULTS
Combined lithium and VPA treatment synergistically enhances FGF-21 mRNA and protein levels in neurons Primary neuronal cultures of CGCs from rats were treated with lithium, VPA or their combination at day in vitro (DIV)-6 for 48 h, and then collected for microarray or real-time q-PCR. Treatment with a combination of lithium chloride (3 mM) and VPA (0.8 mM) synergistically boosted mRNA levels of FGF-21 approximately 15-fold, as detected using the NimbleGen Gene Expression Array (Supplementary Table S1 ). Real-time q-PCR confirmed that FGF-21 mRNA levels were moderately increased by lithium (Supplementary Figure S2a ), but not altered by VPA (Supplementary Figure  S2b) ; however, mRNA levels were synergistically increased by cotreatment with lithium and VPA in a time-dependent manner (Figures 1a and b) . The synergistic elevation of FGF-21 mRNA levels plateaued after 2 days of co-treatment and lasted at least 7 days. When using ELISA, we found that FGF-21 protein in both the lysates and the culture medium was robustly elevated after combined treatment with lithium and VPA for 3 or 7 days (Figure 1c) . Potentiation of FGF-21 protein levels by lithium-VPA co-treatment for 3 or 7 days was also confirmed by western blotting analysis (Figure 1d ).
In primary hippocampal and cortical neurons, lithium, but not VPA, also significantly increased FGF-21 mRNA levels, and more than additive increases were observed when these neurons were co-treated with lithium and VPA (Figure 1e ). In addition, FGF-21 mRNA levels in the brain of CD1 mice were significantly elevated ), or lithium carbonate (3 g kg − 1 )-sodium VPA (25 g kg − 1 ) in combination. Four weeks later, whole brains were dissected and used for RNA extraction. FGF-21 mRNA levels were analyzed by q-PCR. (g) CGCs were treated with 3 mM Li, 0.8 mM VPA or their combination at DIV-6. Two days later, cells were lysed and mRNA levels were measured using q-PCR methodology. Quantified data are means ± s.e.m. and analyzed by one-way ANOVA, n = 4-5; *Po 0.05; **Po0.01; ***Po 0.001. (Figure 1f) . The synergistic increase in FGF-21 mRNA levels by lithium-VPA co-treatment in CGCs was highly selective among a spectrum of neurotrophic and neuroprotective proteins, including FGF-15, FGF-23, BDNF, glial cell line-derived neurotrophic factor (GDNF), VEGF-α, platelet-derived growth factor (PDGF)-α, transforming growth factor (TGF)-α, heat-shock protein (HSP)70-1a, HSP70-1b and α-synuclein (α-syn) (Figure 1g ). mRNA levels of these genes were either unaffected by all treatment conditions or modestly increased by mono-treatment with lithium or VPA, however, not synergistically by co-treatment.
We also investigated whether FGF-21 mRNA can be induced by lithium-VPA co-treatment in cells of glial origin. For this study, we employed rat C6 glioma and primary cerebral cortical glial cells, which displayed their typical cell morphologies (Supplementary Figure S3a) . Treatment of C6 cells with 1 mM VPA in conjunction with various concentrations of LiCl resulted in a dose-dependent increase in FGF-21 mRNA levels (Supplementary Figure S3b) . A similar extent (eight-fold) of the increase in FGF-21 mRNA was observed in rat primary cortical glial cultures (Supplementary Figure S3b) .
Synergistic expression of FGF-21 mRNA by lithium and VPA is mediated through GSK-3 and HDAC inhibition, respectively By themselves, the GSK-3 inhibitors SB415286 (SB415) and SB216763 (SB216) had modest effects on FGF-21 mRNA levels in a concentration-dependent manner (Supplementary Figure S5a) . When used with VPA, 10 μM of SB415 mimicked the ability of lithium to cause synergistic increases in FGF-21 mRNA levels (Figure 2a) . Interestingly, SB415 and lithium co-treatment also markedly increased FGF-21 mRNA levels; the largest increase (approximately 40-fold) was observed when SB415, lithium and VPA were all present (Figure 2a) . To further explore the role of GSK-3 inhibition, CGCs were transduced with lentivirus-driven GSK-3β shRNA (sh-GSK-3β) or with scramble control small hairpin RNA (shRNA; sh-cont) immediately after cell plating; the listed shRNA sequence of the studied gene is shown in Supplementary  Table S2 . At DIV-6, cells were collected for western blotting to detect total GSK-3β protein levels, or alternately, treated with lithium, VPA or their combination for 2 days before collecting. In keeping with our previous findings 30 sh-GSK-3β (#614) robustly reduced GSK-3β protein levels compared with the sh-cont (Figure 2b ). More importantly, after knockdown of the GSK-3β gene, an approximately sixfold increase in FGF-21 mRNA levels was observed. When combined with lithium, there was a 15-fold increase; when combined with VPA, there was a 19-fold increase, and, when combined with both lithium and VPA, there was a 50-fold increase (Figure 2c ). The transduction efficiency of lentivirus-mediated control shRNA containing a gene encoding green fluorescence protein (GFP) was estimated to be about 50% in CGCs (Supplementary Figures S4a and b) . We also assessed the effects GSK-3α knockdown on FGF-21 mRNA levels. When a specific sh-GSK-3α construct (#595) was transduced into CGCs via lentivirus to knockdown GSK-3α by about 50%, a relatively small The effects of these HDAC inhibitors alone were also assessed. Quantified data are means ± s.e.m. and analyzed by one-way ANOVA, n = 3; *Po 0.05; **Po 0.01; ***Po 0.001. increase in FGF-21 mRNA level was observed either in the absence or presence of lithium or VPA, whereas a nearly 20-fold increase was observed with GSK-3α shRNA used in the presence of both lithium and VPA, compared with about a 12-fold increase induced by lithium-VPA co-treatment ( Supplementary Figures S4c  and d) .
Interestingly, augmenting FGF-21 mRNA levels with lithium and VPA was mimicked by co-treatment with lithium and the structurally similar HDAC inhibitors phenyl butyrate (1 mM; PB) or sodium butyrate (1 mM; SB). However, neither PB nor SB alone affected FGF-21 mRNA levels (Figure 2d) , regardless of concentration (Supplementary Figure S5b) . Similar robust effects were observed when the structurally dissimilar HDAC inhibitors vorinostat (1 μM; SAHA) or trichostatin A (100 nM; TSA) were used in conjunction with lithium (Figure 2e ). TSA itself had no effect on FGF-21 mRNA levels (Supplementary Figure S5c) , but SAHA modestly and dose dependently increased FGF-21 mRNA levels (Supplementary Figure S5d) . MS-275 (5 μM), a class I HDAC-specific inhibitor, also potentiated lithium's effects. In contrast, the class III HDAC inhibitor nicotinamide (10 mM; Nicotin) had only marginal effects when combined with lithium (Figure 2f ). (Figures 3a and b) . The neuroprotective effects of FGF-21 were associated with a rapid increase in phosphorylation levels of Akt-1 Ser473 (Figure 3c ), GSK-3β Ser9 (Figure 3d ) and ERK 44/42 Thr202/Tyr204 ( Figure 3e) ; no changes were observed in total protein levels, indicating activation of Akt-1 and ERK 44/42, and inhibition of GSK-3. Moreover, exogenous FGF-21 blocked glutamate-induced decreases in the phosphorylation of Akt-1, GSK-3β and ERK 44/42 (Figure 3f) .
To investigate whether lithium-VPA co-treatment affects Akt and GSK-3 activity, CGCs were treated with lithium, VPA or their combination for different lengths of time, and phosphorylation Ser473 , p-GSK-3β
Ser9 and p-ERK 44/42 Thr202/Tyr204 . (f) CGCs were pretreated with a combination of Li and VPA for 6 days starting at DIV-6, and then treated with glutamate for 6 h, as described above. Cells were collected for western blotting to determine total and phosphorylated proteins of Akt-1 Ser473 , GSK-3β Ser9 and ERK 44/42 Thr202/Tyr204 . Quantified data are means ± s.e.m. and analyzed by one-way ANOVA, n = 4; *Po 0.05; **P o0.01; ***P o0.001. Ser473 phosphorylation, which returned to baseline within 1-2 h; VPA alone had no effect (Figures 4a and c) . Notably, co-treatment with lithium and VPA robustly potentiated the lithium-induced Akt-1 Ser473 phosphorylation, with a detectable increase at 10 min, a maximal response at 2 h and a long-lasting twofold increase at least 7 days after treatment (Figures 4a and d) . Furthermore, the presence of VPA also potentiated lithium-induced GSK-3β Ser9 phosphorylation, whereas VPA alone had no effect (Supplementary Figures S6a  and b) . In addition, levels of phosphorylated ERK 44/42 Thr202/Tyr204 were modestly increased by lithium-VPA co-treatment (Supplementary Figure S6c ). FGF-21 is involved in lithium-VPA's neuroprotective effects: the role of Akt-1 Because exogenous FGF-21 activated Akt-1 Ser473 (Figure 3c ), we next used lentivirus-mediated knockdown of Akt-1 to assess whether Akt-1 also acts as an upstream regulator of FGF-21 expression. CGCs were transduced with five Akt-1 shRNA constructs at the time of plating. Construct #936 was found to be the most effective in reducing total Akt-1 protein levels measured at DIV-6 (Supplementary Figure S7a) . This Akt-1 knockdown was associated with a significant reduction in basal and co-treatment-induced FGF-21 mRNA levels (Figures 5a and b) . Akt-1 knockdown also markedly attenuated the neuroprotection induced by FGF-21 recombinant protein or lithium-VPA co-treatment (Figure 5c ).
To investigate whether FGF-21 expression mediates the synergistic neuroprotection induced by lithium-VPA co-treatment, we transduced CGCs with five constructs of lentivirus-mediated sh-FGF-21. Construct #373 decreased baseline mRNA levels the most (Supplementary Figure S7b) and lithium-VPA co-treatmentboosted FGF-21 levels (Figure 5d ) by about 50%. In turn, this FGF-21 knockdown markedly decreased phosphorylated Akt-1
Ser473
induced by lithium-VPA co-treatment for 2 or 24 h (Figure 5e ). In addition, sh-FGF-21-induced FGF-21 knockdown blocked cotreatment-induced neuroprotection by about 50% (Figure 5f ). DISCUSSION FGF-21 is considered to be a major metabolic regulator targeting the liver, pancreatic islets and adipose tissue to regulate glucose and lipid metabolism. 31 The present study provides the first evidence that FGF-21 is expressed in primary brain neurons. Furthermore, we demonstrated that FGF-21 mRNA and protein expression levels are modestly enhanced by lithium treatment, and remarkably boosted by lithium and VPA co-treatment (Figure 1 ). In the case of CGCs co-treated with lithium and VPA, the increase in FGF-21 mRNA levels was synergistic (15-20 fold), persistent (lasting at least 7 days) and highly selective among a list of neurotrophic and neuroprotective molecules examined (Figure 1) . It is worth noting that even the closely related FGF family members FGF-15 and 23 were unaffected. This study also demonstrated that the robust induction of FGF-21 mRNA levels by lithium-VPA co-treatment was mediated via GSK-3 and HDAC inhibition, respectively (Figure 2 ). Thus, a pharmacological GSK-3 inhibitor SB415 as well as shRNA-mediated GSK-3β knockdown robustly mimicked lithium's ability to upregulate FGF-21 when used with VPA. Interestingly, lithium in conjunction with SB415 or GSK-3 shRNA also markedly increased FGF-21 mRNA; levels were further increased to 40-to 50-fold when VPA was present. These potentiating effects of GSK-3 inhibitors or gene silencing likely reflect more severe inhibition of GSK-3 activity due to enhanced serine phosphorylation and decreased tyrosine phosphorylation of this kinase by these treatments. 32 Conversely, VPA's effect on FGF-21 induction in the presence of lithium was mimicked by structurally similar (PB and SB) and dissimilar (SAHA and TSA) Figure 4 . Co-treatment with lithium and VPA markedly extended lithium-induced Akt-1 activation. CGCs were treated with 3 mM Li, 0.8 mM VPA or their combination for the indicated times starting at DIV-6, then were collected at DIV-7 (a and c) or DIV-13 (b and d) for western blotting. Quantified data are means ± s.e.m. and analyzed by one-way ANOVA, n = 4; *Po0.05; **P o0.01; ***P o0.001. To define the functional role of FGF-21 in primary brain neurons, we demonstrated that exogenous FGF-21 completely blocked glutamate-induced excitotoxicity and apoptosis in aging CGCs, echoing the neuroprotective effects observed with lithium-VPA co-treatment (Figure 3) . Adding FGF-21 also rapidly increased p-Akt-1
Ser473 levels, as well as its downstream mediator p-GSK--3β Ser9 ; it also induced a somewhat delayed increase in p-ERK 44 /42 Thr202/Tyr204 levels. Akt is a major cell-survival protein kinase with well-established neuroprotective properties, and its roles in neuroprotection through phosphorylating diverse apoptotic and protective proteins are well documented. 22 It is notable that FGF-21 improves pancreatic β-cell function and survival by activating Akt and ERK, suggesting that FGF-21's insulin-like ability to maintain glucose homeostasis may involve these signaling pathways. 33 As we reported previously, lithium transiently increases p-Akt-1 levels. 34 In this study, we showed that cotreatment with lithium and VPA markedly prolonged the duration of Akt-1 activation for at least 1 week (Figure 4) . shRNA-elicited Akt-1 knockdown reduced basal and lithium-VPA co-treatmentinduced FGF-21 levels, suggesting that Akt-1 is also an upstream mediator of FGF-21 expression and serves as a feed-forth regulator ( Figure 5 ). Akt-1 knockdown also attenuated the neuroprotection elicited by exogenous FGF-21 and lithium-VPA co-treatment, further supporting that Akt-1 has a critical role in protecting against glutamate excitotoxicity. Importantly, shRNA-mediated silencing of FGF-21 markedly suppressed lithium-VPA-induced neuroprotection from excitotoxicity, suggesting that FGF-21 induction is at least partially responsible for the synergistic protective effects in aging CGCs ( Figure 5 ). Figure 5g illustrates how Akt-1 is both upstream and downstream of FGF-21 and the manner in which FGF-21 is a critical target for co-treatment with lithium and VPA to induce synergistic neuroprotective effects.
Glutamate-induced excitotoxicity in primary neurons is mediated by overstimulation of NMDA receptors. 27 Growing evidence has linked glutamate excitotoxicity in discrete brain areas to diverse neurodegenerative and neuropsychiatric conditions, including stroke, traumatic brain injury, Huntington's disease, (a) CGCs were transduced with sh-cont or sh-Akt-1 at the time of cell plating, and collected for FGF-21 mRNA levels at DIV-6 (n = 3, two tailed unpaired t-test). (b) CGCs were transduced with sh-Akt-1 as described above and then treated with Li-VPA at DIV-6 and collected at DIV-8 for FGF-21 mRNA detection using q-PCR analysis (n = 4, two-tailed unpaired t-test). (c) CGCs at DIV-6 were treated with 5 nM FGF-21 recombinant protein, or a combination of 3 mM Li and 0.8 mM VPA, followed by exposure to 100 μM glutamate at DIV-12 for 24 h. Cell viability was determined by using an MTT assay at DIV-13 (n = 3, one-way ANOVA). (d) CGCs were transduced with sh-cont or sh-FGF-21 construct at the time of cell plating and co-treated with 3 mM Li and 0.8 mM VPA at DIV-6, then collected for q-PCR assay of FGF-21 mRNA levels at DIV-8 (n = 4, two-tailed unpaired t-test). (e) CGCs transduced with sh-cont or sh-FGF-21 as described were co-treated with 3 mM Li and 0.8 mM VPA starting from DIV-6, followed by western blotting analysis (n = 3, one-way ANOVA). (f) At DIV-6, CGCs were treated with 3 mM Li, 0.8 mM VPA or their combination for 6 days followed by exposure to glutamate for 24 h. Cell viability was determined at DIV-13 using an MTT assay (n = 3, twotailed unpaired t-test). (g) FGF-21 was selectively and robustly induced in aging primary brain neurons by lithium-VPA co-treatment through inhibition of GSK-3 and HDACs, respectively. Lithium and VPA co-treatment induces long-lasting activation of Akt-1 via increased Ser473 phosphorylation, and this Akt-1 activation is involved in FGF-21 gene expression. Lithium alone only transiently activates Akt-1 and modestly elevates FGF-21 mRNA levels, whereas VPA alone is ineffective. FGF-21 completely protects primary neurons from glutamate-induced excitotoxicity and apoptosis, and these protective effects in return require FGF-21-induced Akt-1 activation. Thus, Akt-1 serves as a feed-forth regulator for the upstream and downstream actions of FGF-21. FGF-21 induction contributes, at least in part, to the synergistic neuroprotective effects of lithium-VPA co-treatment in aging neurons. Quantified data are means ± s.e.m. *P o0.05; **P o0.01; ***P o0.001.
Alzheimer's disease, amyotrophic lateral sclerosis (ALS), spinal cord injury, major depression and bipolar disorder. 21, 22 In preclinical animal models of ALS, Huntington's disease and traumatic brain injury, we reported that co-treatment with lithium and VPA was more potent and effective than mono-treatment in inducing neuroprotective molecules, improving behavioral performance and prolonging life-span. [35] [36] [37] Available data set of the expression profile of the human genome indicated that FGF-21 transcript was detectable in the human prefrontal cortex 38 (BrainCloud, braincloud.jhmi.edu). Our study showed that FGF-21 mRNA was induced in the brain of mice after chronic dietary administration with both lithium and VPA, whereas mono-treatment with either drug was ineffective (Figure 1f) . Further, we provided evidence that FGF-21 can be induced by lithium-VPA co-treatment in rat glioma cells and primary glial cells derived from rat cerebral cortex (Supplementary Figure S3) . Our ongoing studies are investigating whether the pathophysiology of the above-mentioned experimental brain disorders is associated with FGF-21 dysregulation, and whether lithium and VPA combined treatment upregulates FGF-21 expression levels to induce beneficial effects. In this context, two recent studies showed that FGF-21 via acting with its co-receptor β-Klotho on the suprachiasmatic nucleus in mouse hypothalamus regulates brain circadian clock and female reproduction through neuroendocrine control, 39, 40 supporting critical neurobiological roles of FGF-21 in the CNS.
It is worth commenting here that the etiology of bipolar disorder is poorly understood. One current working hypothesis is that its pathogenesis involves an interplay between environmental and genetic factors that affect brain plasticity. 41 Although lithium and VPA have been mainstay therapeutic agents for bipolar disorder, only a fraction of individuals with bipolar patients respond to mono-treatment with either drug, and combined lithium and VPA treatment is a rational therapy for these refractory patients. 42, 43 Interestingly, patients with bipolar disorder have higher rates of type 2 diabetes mellitus than the general population, and bipolar patients with diabetes have a more severe bipolar disease course and are more resistant to therapy. 44 In light of these clinical observations and our current results, one intriguing possibility that warrants further clinical investigation is that the etiology of bipolar disorder may involve a deficiency in FGF-21 expression levels in the brain and peripheral tissues, and this deficiency might be overcome by lithium and VPA co-administration.
In conclusion, our novel results demonstrate that FGF-21 is expressed in brain neurons, and that its expression levels are boosted by combined treatment with the mood stabilizers lithium and VPA via the inhibition of GSK-3 and HDACs, respectively. This study also defines a new functional role for FGF-21 in neuroprotection against glutamate-induced excitotoxicity, similar to the effects of lithium and VPA co-treatment. Here, Akt-1 activation acts as an upstream regulator of FGF-21 expression and a downstream mediator for FGF-21-induced neuroprotection. We provide evidence that FGF-21 induction is part of the molecular mechanisms underlying the synergistic neuroprotection induced by mood stabilizers. Our study raises the intriguing possibility that a number of CNS disorders, notably those linked to excitotoxicity, may involve FGF-21 deficiency and that this growth factor could serve as a therapeutic target for certain CNS pathological conditions.
